Down-regulation of matrix metalloproteinase-7 inhibits metastasis of human anaplastic thyroid cancer cell line

Epigenetic drugs such as histone deacetylase inhibitors (HDACIs) possess anticancer properties due to its ability to regulate genes associated with tumor growth, differentiation, apoptosis and metastasis. In addition to its apoptotic effect, phenylbutyrate (PB), a carboxylic acid HDACI, inhibited an anaplastic (ATC) thyroid cancer cell line ARO from penetrating a matrigel coated transwell with concomitant suppression of a metastasis-associated gene, matrix metalloproteinase-7 (MMP-7) and stimulation of a transformation suppressor protein, reversion-inducing- cysteine-rich protein with Kazal motifs without affecting MMP-2 expression levels. Direct evidence suggesting MMP-7 down-regulated cancer metastasis came from the observation of a decreased pulmonary metastasis in SCID mice xeno-transplanted with MMP-7-knocked-down ARO cells. In addition, H-89, a protein kinase A inhibitor, remarkably restored the down-regulaed MMP-7 level treated by PB. Thus, the suppressive effect of PB on MMP-7 was partially carried out through H3 phosphoacetylation. To conclude, our findings suggest PB inhibits MMP-7 expression epigenetically through phosphoacetylation of histone proteins, and thereby, reduced invasive ability of an ATC thyroid cancer cell line.

[1]  B. Schuettengruber,et al.  Activation of the Mouse Histone Deacetylase 1 Gene by Cooperative Histone Phosphorylation and Acetylation , 2002, Molecular and Cellular Biology.

[2]  G. Gores,et al.  Calpains Can Do It Alone: Implications for Cancer Therapy , 2003, Cancer biology & therapy.

[3]  T. Shiomi,et al.  MT1-MMP and MMP-7 in invasion and metastasis of human cancers , 2003, Cancer and Metastasis Reviews.

[4]  J-D Lin,et al.  Characterization of a thyroid hormone-mediated short-loop feedback control of TSH receptor gene in an anaplastic human thyroid cancer cell line. , 2002, The Journal of endocrinology.

[5]  M. Hamaguchi,et al.  Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions , 2006, Histopathology.

[6]  M. Maio,et al.  Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications , 2007, Journal of cellular physiology.

[7]  D. Fishman,et al.  Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. , 2006, Cancer letters.

[8]  M. Goh,et al.  Phenylbutyrate inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo basement membrane invasion assay , 2002, International journal of cancer.

[9]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[10]  J. Davie.  Inhibition of histone deacetylase activity by butyrate. , 2003, The Journal of nutrition.

[11]  K. Chang,et al.  Overexpression of thyroid hormone receptor beta1 is associated with thyrotropin receptor gene expression and proliferation in a human thyroid carcinoma cell line. , 2000, The Journal of endocrinology.

[12]  T. Minamoto,et al.  Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. , 2002, Gastroenterology.

[13]  Y. Okada,et al.  Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers , 1999, Gut.

[14]  Y Ikawa,et al.  Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Tomoyuki Shirai,et al.  MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. , 2005, Cancer cell.

[16]  David B. Alexander,et al.  The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis , 2001, Cell.

[17]  S. Korem,et al.  Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma. , 2002, The Israel Medical Association journal : IMAJ.

[18]  M. Mareel,et al.  Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. , 2001, Journal of cell science.

[19]  Minoru Yoshida,et al.  [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[20]  K. Glaser,et al.  Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. , 2003, Molecular cancer therapeutics.

[21]  Yasuhiro Ito,et al.  Inverse relationships between the expression of MMP‐7 and MMP‐11 and predictors of poor prognosis of papillary thyroid carcinoma , 2006, Pathology.

[22]  C. Langford,et al.  Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes. , 2007, Genome research.

[23]  H. Kitayama,et al.  RECK Forms Cowbell-shaped Dimers and Inhibits Matrix Metalloproteinase-catalyzed Cleavage of Fibronectin* , 2009, Journal of Biological Chemistry.

[24]  C. Benz,et al.  Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. , 2002, Molecular cancer therapeutics.

[25]  Hiroyuki Yamamoto,et al.  Role of Matrix Metalloproteinase-7 (Matrilysin) in Human Cancer Invasion, Apoptosis, Growth, and Angiogenesis , 2006, Experimental biology and medicine.

[26]  A. Sparreboom,et al.  Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review , 2005, Molecular Pharmacology.

[27]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[28]  Victor G Corces,et al.  Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. , 2004, Trends in genetics : TIG.

[29]  W. Hung,et al.  Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. , 2003, Cancer research.

[30]  V. Alves,et al.  Metalloproteinase‐9 immunoexpression and angiogenesis in thyroid follicular neoplasms: Relation to clinical and histopathologic features , 2000, Head & neck.

[31]  T. Terada,et al.  Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas , 2001, Virchows Archiv.

[32]  R. Rubenstein,et al.  Sodium 4-phenylbutyrate downregulates HSC70 expression by facilitating mRNA degradation. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[33]  R. Kawata,et al.  [Study of matrix metalloproteinase-2 and -9 in thyroid papillary cancer]. , 2000, Nihon Jibiinkoka Gakkai kaiho.

[34]  K. Struhl.  Histone acetylation and transcriptional regulatory mechanisms. , 1998, Genes & development.

[35]  H. Duan,et al.  Histone Deacetylase Inhibitors Down-Regulate bcl-2 Expression and Induce Apoptosis in t(14;18) Lymphomas , 2005, Molecular and Cellular Biology.

[36]  H. Osada,et al.  RECK negatively regulates matrix metalloproteinase-9 transcription. , 2009, Cancer research.

[37]  R. Ramer,et al.  Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. , 2008, Journal of the National Cancer Institute.

[38]  G. Tuszynski,et al.  The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis , 2009, Pathology Oncology Research.

[39]  E. Marchioni,et al.  Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines. , 2004, Thyroid : official journal of the American Thyroid Association.

[40]  K. Somasundaram,et al.  Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB , 2004, Oncogene.

[41]  J. Peedicayil.  Epigenetic therapy--a new development in pharmacology. , 2006, The Indian journal of medical research.

[42]  H. Gharib,et al.  Anaplastic thyroid carcinoma: current diagnosis and treatment. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  David M. Thomas,et al.  RECK—a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer , 2007, Cancer and Metastasis Reviews.

[44]  M. Mareel,et al.  Clinical, cellular, and molecular aspects of cancer invasion. , 2003, Physiological reviews.

[45]  E. Wang,et al.  SRC Proximal and Core Promoter Elements Dictate TAF1 Dependence and Transcriptional Repression by Histone Deacetylase Inhibitors , 2004, Molecular and Cellular Biology.

[46]  L. Matrisian,et al.  Structure and expression of the human gene for the matrix metalloproteinase matrilysin. , 1994, The Journal of biological chemistry.

[47]  M. Rath,et al.  Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. , 2009, Oncology reports.

[48]  H. Allgayer,et al.  Urokinase receptor, MMP‐1 and MMP‐9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies , 2009, International journal of cancer.

[49]  L. Coussens,et al.  RECKing MMP function: implications for cancer development. , 2002, Trends in cell biology.

[50]  B. Nankova,et al.  Butyrate, a gut-derived environmental signal, regulates tyrosine hydroxylase gene expression via a novel promoter element. , 2005, Brain research. Developmental brain research.

[51]  C. López-Otín,et al.  Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. , 2004, The International journal of developmental biology.

[52]  C. Benz,et al.  Clinical development of histone deacetylase inhibitors as anticancer agents. , 2005, Annual review of pharmacology and toxicology.